|
CAR-T cell Clinical Trials
4 actively recruiting trials across 3 locations
No change since May 2026
Also known as: CAR-T cell therapy
Pipeline
Early 1: 1Phase 1: 1Phase 1/2: 2
Top Sponsors
- University of Texas Southwestern Medical Center1
- National Cancer Institute (NCI)1
- Memorial Sloan Kettering Cancer Center1
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS1
Indications
- Cancer3
- Diffuse Large B-Cell Lymphoma2
- System; Sclerosis1
- Polymyositis1
- ANCA Associated Vasculitis1
Other1 trial
Bethesda, Maryland1 trial
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
National Institutes of Health Clinical Center
Phase 1
Basking Ridge, New Jersey1 trial
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Early 1
Dallas, Texas1 trial
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
University of Texas Southwestern Medical Center
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.